Opportunity Information: Apply for PA 06 435
Apply for PA 06 435
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Phase II Developmental Research in Cancer Prognosis and Prediction (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Dec 5, 2008 and posted on May 23, 2006.
- Applicants must submit their applications by May 7, 2009 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: County governments City or township governments State governments Public housing authorities/Indian housing authorities Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Native American tribal governments (Federally recognized) Private institutions of higher education Special district governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply. Applicants may submit more than one application, provided each application is scientifically distinct.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Phase II Developmental Research in Cancer Prognosis and Prediction (R33) is a National Institutes of Health (NIH) funding opportunity that supports projects aimed at improving how clinicians forecast cancer outcomes and anticipate how patients will respond to specific therapies. The focus is on Phase II-style developmental research: applicants are expected to move beyond basic discovery and instead evaluate the real-world utility of promising strategies, then pilot their application in ways that can inform clinical decision making. In practical terms, the program is looking for studies that test whether using a new prognostic or predictive approach can meaningfully benefit a clearly defined group of cancer patients, such as by improving treatment selection, reducing unnecessary toxicity, or better identifying patients who will or will not respond to a given intervention.
The FOA (Funding Opportunity Announcement) calls for R33 grant applications, which are designed to support later-stage development and assessment of tools, models, biomarkers, algorithms, assays, imaging approaches, or other strategies intended to determine prognosis or predict therapeutic response. A key theme is clinical usefulness: the proposed work should be structured to examine whether applying the strategy changes decisions or outcomes in a way that matters for patient care. Rather than simply showing that a marker correlates with outcome, the project should be built to evaluate utility and to pilot implementation, ideally generating evidence that the approach could be incorporated into clinical workflows or used to guide care for the target patient population.
Administratively, this is a discretionary grant program under the NIH, categorized broadly under education/health activities, and associated with CFDA number 93.394 (Cancer Detection and Diagnosis Research). The announcement anticipated approximately four awards and did not require cost sharing or matching. The opportunity used multiple receipt dates rather than a single deadline, with the posting date listed as May 23, 2006, and a final listed closing date of May 7, 2009, with an archive date of June 7, 2009.
Eligibility for this FOA was broad, encompassing many types of U.S. entities and also allowing foreign institutions. Eligible applicants included state, county, and local governments; special district governments; public housing authorities/Indian housing authorities; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations both with and without 501(c)(3) status; for-profit organizations other than small businesses; and federally recognized Native American tribal governments as well as other tribal organizations. The FOA also clarified that eligible federal agencies could apply and that faith-based and community-based organizations were eligible. Applicants were permitted to submit more than one application as long as each submission was scientifically distinct.
Overall, the opportunity is best understood as NIH support for taking a candidate prognostic or predictive strategy that shows promise and putting it through a more applied, clinically oriented evaluation. The intent is to produce tools and evidence that can sharpen clinical decision making in oncology by demonstrating that the strategy, when used in practice for a specific patient group, has the potential to improve outcomes or otherwise provide tangible clinical benefit.
The full announcement was made available through the NIH grants website under Funding Opportunity Number PA-06-435, with an additional information link provided at http://grants.nih.gov/grants/guide/pa-files/PA-06-435.html. For access or linking issues, the contact listed was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: Phase II Developmental Research in Cancer Prognosis and Prediction (R33) - NIH (PA-06-435)
What is this funding opportunity?
This is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) for R33 grants titled "Phase II Developmental Research in Cancer Prognosis and Prediction (R33)." It supports projects focused on improving how clinicians forecast cancer outcomes (prognosis) and predict how patients will respond to specific therapies (prediction of therapeutic response).
What is the main goal of the program?
The main goal is to move beyond basic discovery and evaluate the real-world, clinical usefulness of promising prognostic or predictive strategies. The FOA emphasizes studies designed to test whether applying a strategy can improve clinical decision making for a clearly defined group of cancer patients.
What does "Phase II-style developmental research" mean in this FOA?
In this FOA, Phase II-style developmental research refers to later-stage work that goes past identifying or correlating markers with outcomes. Applicants are expected to evaluate practical utility (whether the approach helps in care decisions) and to pilot application or implementation in ways that can inform clinical decision making.
What kinds of projects are encouraged?
Projects are encouraged that assess tools or strategies intended to determine prognosis or predict therapeutic response, and that are structured to examine whether using the strategy meaningfully changes decisions or outcomes in patient care. The focus is on applied evaluation and piloting real-world use rather than basic discovery alone.
What types of strategies or technologies can be supported?
The FOA describes support for later-stage development and assessment of approaches such as tools, models, biomarkers, algorithms, assays, imaging approaches, or other strategies aimed at determining prognosis or predicting therapeutic response.
What is meant by "clinical usefulness" in this opportunity?
Clinical usefulness means the project should be designed to test whether applying the prognostic or predictive strategy affects clinical decisions or patient outcomes in ways that matter for patient care. The FOA specifically contrasts this with simply demonstrating that a marker correlates with an outcome.
What are examples of the kinds of patient benefits the FOA is looking for?
The FOA highlights potential benefits such as improving treatment selection, reducing unnecessary toxicity, and better identifying patients who will or will not respond to a given intervention, for a clearly defined cancer patient population.
Does the FOA require focusing on a specific patient population?
Yes. The FOA emphasizes testing whether a new prognostic or predictive approach benefits a clearly defined group of cancer patients, with evidence that could inform clinical decision making for that target population.
Is this FOA about discovering new biomarkers from scratch?
The FOA emphasizes moving beyond basic discovery. Rather than focusing on discovery alone, applicants are expected to evaluate the real-world utility of promising strategies and pilot their application in clinically oriented ways.
What grant mechanism is used?
The FOA calls for R33 grant applications. In this context, the R33 is used to support later-stage development and assessment of prognostic or predictive strategies and to generate evidence about clinical utility and potential incorporation into clinical workflows.
Who is the funding agency?
The funding agency is the National Institutes of Health (NIH).
What is the Funding Opportunity Number?
The Funding Opportunity Number is PA-06-435.
Where can the full announcement be found?
The full announcement was made available through the NIH grants website at: http://grants.nih.gov/grants/guide/pa-files/PA-06-435.html
What is the CFDA number associated with this opportunity?
The FOA is associated with CFDA number 93.394, labeled "Cancer Detection and Diagnosis Research."
How is this program categorized administratively?
Administratively, it is described as a discretionary grant program under the NIH and categorized broadly under education/health activities.
How many awards were anticipated?
The announcement anticipated approximately four awards.
Is cost sharing or matching required?
No. The FOA did not require cost sharing or matching.
What were the key dates for this FOA?
The posting date was May 23, 2006. The final listed closing date was May 7, 2009, and the archive date was June 7, 2009. The opportunity used multiple receipt dates rather than a single deadline.
Did this opportunity have a single application deadline?
No. The FOA used multiple receipt dates rather than a single deadline.
Who was eligible to apply?
Eligibility was broad and included many types of U.S. entities, and foreign institutions were also allowed. Eligible applicants included state, county, and local governments; special district governments; public housing authorities/Indian housing authorities; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations other than small businesses; federally recognized Native American tribal governments; and other tribal organizations.
Are foreign institutions eligible?
Yes. The FOA allowed foreign institutions to apply.
Are nonprofit organizations eligible even if they do not have 501(c)(3) status?
Yes. The FOA lists nonprofit organizations with and without 501(c)(3) status as eligible applicants.
Are for-profit organizations eligible?
Yes. The FOA included for-profit organizations other than small businesses as eligible.
Are tribal governments and tribal organizations eligible?
Yes. The FOA included federally recognized Native American tribal governments and also other tribal organizations as eligible applicants.
Are faith-based and community-based organizations eligible?
Yes. The FOA clarified that faith-based and community-based organizations were eligible.
Can federal agencies apply?
Yes. The FOA clarified that eligible federal agencies could apply.
Can an applicant submit more than one application?
Yes. Applicants were permitted to submit more than one application, as long as each submission was scientifically distinct.
What kind of evidence should a project aim to generate?
The FOA emphasizes generating evidence that the approach could be incorporated into clinical workflows or used to guide care for the target patient population, by demonstrating that using the strategy can change decisions or outcomes in clinically meaningful ways.
Does the FOA prioritize implementation into clinical workflows?
It emphasizes piloting application and implementation in ways that can inform clinical decision making, and ideally generating evidence that the approach could be incorporated into clinical workflows for the target patient group.
Who should be contacted if there are problems accessing the FOA link?
For access or linking issues, the contact listed was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Shared Neurobiology of Fragile X Syndrome and Autism (R03)
Previous opportunity: Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 06 435
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 06 435) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Development of Frontal Cortex and Limbic System and their roles in Drug Abuse or Mental Health (R21) Apply for PA 06 445 Funding Number: PA 06 445 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) Apply for PAR 06 476 Funding Number: PAR 06 476 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral and Integrative Treatment Development Program (R21) Apply for PA 06 487 Funding Number: PA 06 487 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 06 488 Funding Number: PA 06 488 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) Apply for PA 06 496 Funding Number: PA 06 496 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) Apply for PA 06 497 Funding Number: PA 06 497 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis(R21) Apply for PA 06 499 Funding Number: PA 06 499 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R03) Apply for PA 06 502 Funding Number: PA 06 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R21) Apply for PA 06 501 Funding Number: PA 06 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute (NCI) Cancer Education and Career Development Program (R25) Apply for PAR 06 511 Funding Number: PAR 06 511 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 06 461 Funding Number: PA 06 461 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33) Apply for PA 06 462 Funding Number: PA 06 462 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PA 06 463 Funding Number: PA 06 463 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 06 520 Funding Number: PAR 06 520 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 06 521 Funding Number: PAR 06 521 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research for the Prevention and Control of Diabetes and Obesity (R18) Apply for PAR 06 532 Funding Number: PAR 06 532 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 06 541 Funding Number: PAR 06 541 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21) Apply for PA 07 022 Funding Number: PA 07 022 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Focal Cognitive Deficits in CNS Disorders (R03) Apply for PA 07 034 Funding Number: PA 07 034 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Focal Cognitive Deficits in CNS Disorders (R21) Apply for PA 07 035 Funding Number: PA 07 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 435", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.